Xeris Biopharma Holdings Inc (XERS) reported its financial results for the third quarter of fiscal 2025, revealing earnings per share (EPS) of $0.00, matching Wall Street's consensus estimate but falling short of expectations in terms of revenue. The company generated $0.1 billion in revenue, equal to analyst forecasts but indicating potential challenges in operational performance.
The company's EPS of $0.00 came in at the expected level, yet the lack of growth in revenue raises concerns about its market position. Xeris Biopharma, based in Chicago, Illinois, is a biopharmaceutical company focused on developing and commercializing products across various therapies, including Recorlev for endogenous Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis.
Xeris Biopharma will host an earnings conference call to discuss these results and provide additional insights into its business performance. The company is also advancing its pipeline, notably with XP-8121, a phase III-ready treatment for hypothyroidism.
Investors are encouraged to review the full earnings release and listen to management's commentary for comprehensive context on the quarter's performance and future outlook. The company has a market capitalization of $1.25 billion and an EPS of -0.21 on a trailing twelve-month basis, with upcoming earnings scheduled for August 4, 2026, where EPS is estimated at 0.0612 and revenue at $0.1 billion.